GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia

GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present groundbreaking data from two studies at the Keystone Symposia on Vaccinology. The presentations will focus on the company's GEO-CM04S1 vaccine candidate and its multi-antigen vaccine technology, demonstrating their ability to induce protective immunity against a range of SARS-CoV-2 variants, from Alpha to Omicron. This development is crucial as it addresses the need for vaccines that can provide broad-spectrum immunity against emerging variants, especially for immunocompromised populations where current vaccines may fall short.

The first presentation, led by GeoVax scientist Pratima Kumari, PhD, will detail how the company's MVA-vectored multi-antigen COVID-19 vaccines have shown promise in preclinical animal models. The second, by Georgia State University scientist Amany Elsharkawy, PhD, will highlight the GEO-CM04S1 vaccine candidate's cross-reactivity against original SARS-CoV-2 B.1 and Omicron subvariant XBB.1.5. These findings underscore the potential of GeoVax's technology to offer more durable and effective protection against COVID-19, particularly for vulnerable groups.

Mark Newman, PhD, GeoVax's Chief Scientific Officer, emphasized the importance of inducing broadly specific immune responses, including T-cell responses to both Spike and Nucleocapsid viral proteins. This approach could revolutionize how vaccines are developed for populations with compromised immune systems, offering hope for more effective prevention strategies against COVID-19 and its variants. GeoVax's participation in the Keystone Symposia highlights its leadership in leveraging next-generation vaccine technologies to combat infectious diseases and enhance global preparedness against future pandemics.